Get the Stockscreener App
0.4304
5.39%
-0.0245
After Hours:
.44
0.0096
+2.23%
Cognition Therapeutics Inc Stock (CGTX) Latest News
Chardan Capital Reaffirms Buy Rating for Cognition Therapeutics (NASDAQ:CGTX) - Defense World
Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD - The Bakersfield Californian
Can Cognition's Zervimesine Tackle Dry AMD? New Research Reveals Promising Cellular Rescue - StockTitan
Cognition Therapeutics Reports Positive Futility Analysis Of Zervimesine In Geographic Atrophy - Nasdaq
Zervimesine shows promise in Phase 2 trial for dry AMD By Investing.com - Investing.com South Africa
Zervimesine shows promise in Phase 2 trial for dry AMD - Investing.com
Cognition Therapeutics Successfully Passes Pre-defined - GlobeNewswire
Cognition Therapeutics Successfully Passes Pre-defined Futility Analysis of Phase 2 Study of ... - The Bakersfield Californian
Can This Small Biotech's Drug Tackle Both Eye Disease AND Alzheimer's? Phase 2 Data Says Yes - StockTitan
Cognition Therapeutics, Inc. to Co-Host Precision Medicine Workshop at Neuroimmunology Drug Development Summit - Nasdaq
Cognition Therapeutics’ VP of Research Co-hosting Precision - GlobeNewswire
Can This Biomarker Strategy Revolutionize Alzheimer's Treatment? Cognition's 95% Improvement Data - StockTitan
Cognition Therapeutics Announces Publication of Commercial - GlobeNewswire
Cognition Therapeutics develops new drug manufacturing process By Investing.com - Investing.com Nigeria
Cognition Therapeutics develops new drug manufacturing process - Investing.com India
Cognition Therapeutics Announces Publication of Commercial Manufacturing Process for Lead ... - The Bakersfield Californian
Inside Cognition's Game-Changing Manufacturing Process: Will This Transform Alzheimer's Drug Production? - StockTitan
37,108 Shares in Cognition Therapeutics, Inc. (NASDAQ:CGTX) Acquired by SG Americas Securities LLC - Defense World
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Recommendation of “Buy” from Brokerages - Defense World
BIO CEO 2025: Cognition CEO debates policy while advancing CT-1812 - BioWorld Online
B. Riley Cuts Earnings Estimates for Cognition Therapeutics - Defense World
Investors in cash trouble should check out Cognition Therapeutics Inc (CGTX) - SETE News
B. Riley Adjusts Cognition Therapeutics Price Target to $2 From $1.50, Maintains Buy Rating - Marketscreener.com
Cognition Therapeutics Presents Phase 2 Results For Drug To Fight DLB At International Conference - Nasdaq
Cognition Therapeutics Inc (CGTX) receives a Buy rating from B. Riley Securities - Knox Daily
What technical indicators reveal about CGTX stock - US Post News
Director Makes Bold Move with Major Stock Purchase in Cognition Therapeutics - TipRanks
Can Cognition Therapeutics Inc Bounce Back? 52-Week Performance and Analyst Predictions - The InvestChronicle
Is Now The Time To Buy Cognition Therapeutics Inc (NASDAQ: CGTX) Stock? - Stocks Register
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Short Interest Update - Defense World
A Data-Based Look At Cognition Therapeutics Inc (CGTX) - Stocks Register
Cognition’s Positive Phase 2 ‘SHIMMER’ Study of Zervimesine - GlobeNewswire
CGTXCOGNITION THERAPEUTICS INC Latest Stock News & Market Updates - StockTitan
Cognition Therapeutics Reports Positive Topline Results of Zervimesine in SHIMMER Study for Dementia with Lewy Bodies - Nasdaq
Cognition’s Positive Phase 2 ‘SHIMMER’ Study of Zervimesine (CT1812) in Dementia with Lewy - The Bakersfield Californian
New Dementia Drug Achieves Remarkable 91% Reduction in Cognitive FluctuationsPhase 2 Results Revealed - StockTitan
Brokers Issue Forecasts for CGTX FY2024 Earnings - Defense World
Lewy Body Dementia Market Deep Research Report with Forecast - openPR
Cognition Therapeutics (NASDAQ:CGTX) Raised to “Strong-Buy” at Brookline Capital Management - Defense World
70+ Key Companies Advancing in Dry Age-Related Macular Degeneration Clinical Trial Therapeutic Space | DelveInsight - The Malaysian Reserve
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Alzheimer's Disease Clinical and Non-Clinical Studies, Key - openPR
**Cognition Therapeutics (NASDAQ:CGTX) Prepares to Advance Treatment Efforts** ** - Defense World
Dry Age Macular Degeneration Pipeline Insights 2024: Therapies, Clinical Trials, Therapies and Key Companies involved by DelveInsight |Janssen R&D, Belite Bio, Katairo, Cognition Therapeutics - Barchart
Dry Age Macular Degeneration Pipeline Insights 2024: - openPR
Cognition Therapeutics Shows Promising Phase 2 Study Results - TipRanks
Cognition Therapeutics Is Targeting A Critical Form Of Dementia - Nasdaq
Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences - The Manila Times
Cognition Therapeutics Advances DLB Treatment After Positive Phase 2 Results, CEO to Present at JPM Week - StockTitan
Cognition Therapeutics (NASDAQ:CGTX) versus Editas Medicine (NASDAQ:EDIT) Head-To-Head Contrast - Defense World
Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Cognition Therapeutics Reports Promising Phase 2 Results for Dementia with Lewy Bodies Treatment - Citybuzz
Topline Results Are In: Cognition Therapeutics’ Drug To Fight Dementia With Lewy Bodies Shows Encouraging Results In Phase 2 Trial - Nasdaq
Cognition Therapeutics (NASDAQ:CGTX) Will Have To Spend Its Cash Wisely - Simply Wall St
This Biotech Is Already Off To The Races Before The Opening Bell - MSN
B. Riley upgrades Cognition Therapeutics to Buy on Lewy bodies data - Yahoo Finance
6.45%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):